Markets
markets

Investors shrug off new Intel CEO’s first public remarks as chipmakers decline

Lip-Bu Tan’s first public remarks as Intel’s new CEO weren’t enough to keep the company out of a downdraft among major chipmakers.

Intel was one of the worst performers in the chip sector in Tuesday trading, with shares of Nvidia, Arm, Broadcom, and AMD also slumping, among other chipmakers.

To be fair, Tan was only given reins to the struggling US semiconductor icon three weeks ago, but his comments at the chip giant’s Vision conference in Las Vegas on Monday were pretty vague.

Pronouncements such as, “We will redefine some of our strategy and free up the bandwidth,” or, “Some of our noncore business — we will spin it off,” sound a bit underwhelming given the praise showered on the former chief executive of Cadence Design Systems after he was tapped as Intel’s CEO on March 12.

After all, “we need to improve” isn’t exactly a leadership revelation for a company’s whose stock price has collapsed 60% over the past five years, vaporizing $125 billion in market cap.

But turnarounds do take time.

To be fair, Tan was only given reins to the struggling US semiconductor icon three weeks ago, but his comments at the chip giant’s Vision conference in Las Vegas on Monday were pretty vague.

Pronouncements such as, “We will redefine some of our strategy and free up the bandwidth,” or, “Some of our noncore business — we will spin it off,” sound a bit underwhelming given the praise showered on the former chief executive of Cadence Design Systems after he was tapped as Intel’s CEO on March 12.

After all, “we need to improve” isn’t exactly a leadership revelation for a company’s whose stock price has collapsed 60% over the past five years, vaporizing $125 billion in market cap.

But turnarounds do take time.

More Markets

See all Markets
markets

Nike craters after issuing weak revenue guidance

Sportswear kingpin Nike is tumbling on Wednesday morning after saying it doesn’t expect to grow sales this year.

On its fiscal Q3 earnings call, management said that revenue is expected to drop 2% to 4% in the current quarter, and that overall they “expect revenues to be down low-single-digits versus the prior year, with gains in North America offset by declines in Greater China.” That's a disappointment to analysts, who were anticipating 2% growth in Q4, and even more in the latter stages of the year, per Bloomberg.

Nike’s Q3 sales in China — where the company earns about 15% of its revenue — fell 7% to $1.62 billion. The company had issued weak guidance for this quarter considering continued softness in the region. That’s its seventh straight quarter of sales declines in the market. While this quarter’s was decline was less than feared, management warned that more pain is in the offing.

Nike’s turnaround effort “is complex work, and parts of it are taking longer than I'd like,” said CEO Elliott Hill.

Nike’s fiscal Q3 results (the three months ended February) were solid at the headline level:

  • Earnings of $0.35 per share, comfortably above the Wall Street consensus of $0.29 per share compiled by FactSet.

  • $11.28 billion in total revenue, roughly in line with the $11.26 billion estimate.

But the gloomy sales outlook has Wall Street analysts souring on the stock:

  • JPMorgan downgraded the shares to “neutral” from “overweight” and cut its price target to $52 from $86.

  • Citi reduced its target price to $53 from $65,

  • Stifel lowered its price target to $56 from $65,

  • Truist reduced its price target to $57 from $69, and

  • Barclays cut its target price to $67 from $73.

Nike shares are trading near decade lows this month, as tariffs continue to weigh on profits and shipping costs rise amid the war with Iran. As of Tuesday’s close, the stock was down 17% year to date.

Oil-sensitive travel stocks pop following Iran state media reporting on potential war resolution

Travel stocks are surging on Tuesday as oil prices fall following reports from Iranian state media that President Masoud Pezeshkian said the country has the necessary will to end this war, but would only do so with guarantees that prevent the recurrence of aggression.

The war has sent oil prices and refining margins surging this month, causing airlines and cruise lines to cut profit forecasts despite reported high demand.

Following Tuesday’s update, shares of the big four US airlines (Delta Air Lines, United Airlines, American Airlines, and Southwest Airlines) all climbed, along with smaller rivals including JetBlue. US airlines have stopped fuel hedging in recent years, increasing their exposure to upward swings in oil prices.

Cruise stocks also rallied, with Carnival and Norwegian up more than 6% and Royal Caribbean up about 5%.

markets

The FDA is expected to lift restrictions on certain peptides, the NYT reports

The Food and Drug Administration is expected to lift restrictions on certain peptides, allowing the experimental, often injectable substances to be sold by compounding pharmacies, The New York Times reported Tuesday.

The potential move was previously reported by The Wall Street Journal, and teased by Health Secretary Robert F. Kennedy Jr. on the “Joe Rogan Experience” podcast in late February.

Peptides have boomed in popularity recently, with search interest for “peptides” surpassing “ozempic” this month. Many of them are currently understudied and not approved for human use, a rule consumers are able to bypass by purchasing them from suppliers that sell them for, ostensibly, research purposes only.

As reports of the FDA changing its stance of peptides mount, consumer health companies like Hims & Hers and Superpower have been getting ready to roll out their peptide offerings as soon as they get the FDA's blessing.

Peptides have boomed in popularity recently, with search interest for “peptides” surpassing “ozempic” this month. Many of them are currently understudied and not approved for human use, a rule consumers are able to bypass by purchasing them from suppliers that sell them for, ostensibly, research purposes only.

As reports of the FDA changing its stance of peptides mount, consumer health companies like Hims & Hers and Superpower have been getting ready to roll out their peptide offerings as soon as they get the FDA's blessing.

markets

Memory stocks bounce as Bernstein analyst calls TurboQuant fears “overdone”

Memory stocks rose Tuesday, after Bernstein analysts called the recent panic over Google’s TurboQuant AI algorithm “overdone.”

Bernstein analyst Mark Newman wrote:

“[Hard disk drive] and Memory stocks have sold off significantly due in part to fears from Google’s TurboQuant report. This however, should have zero impact on HDD demand and negligible impact on NAND demand. Given the stock sell-off we see this as an attractive entry point for Seagate Technology Holdings, Western Digital and Sandisk’s and upgrade WDC to Outperform.”

All three stocks were up early Tuesday, as was memory chip maker Micron.

Todays rally stands in stark contrast to the pummeling these shares have endured over the last week, after Google Research published a technical paper on March 24 detailing its TurboQuant AI algorithm, which compresses the amount of data associated with AI operations without affecting the accuracy of AI models.

That was seen as a threat to surging AI demand for memory storage, which has supercharged prices for memory chips and memory-related stocks over the last year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.